Novel methods for the remote investigation of emerging substances: Application to kratom.
Journal
Experimental and clinical psychopharmacology
ISSN: 1936-2293
Titre abrégé: Exp Clin Psychopharmacol
Pays: United States
ID NLM: 9419066
Informations de publication
Date de publication:
22 May 2023
22 May 2023
Historique:
pmc-release:
22
11
2024
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
aheadofprint
Résumé
The botanical product commonly called "kratom" is still relatively novel to the United States. Like other natural products marketed as supplements, kratom is highly variable, both in terms of the alkaloids naturally occurring in kratom leaves and in terms of processing and formulation. Kratom products sold in the United States are not well-characterized, nor are daily use patterns among regular users. Surveys and case reports have comprised most of the literature on kratom use among humans. To advance our understanding of real-world kratom use, we developed a protocol for the remote study of regular kratom-using adults in the United States. Our study had three aspects implemented in one pool of participants nationwide: an in-depth online survey, 15 days of ecological momentary assessment (EMA) via smartphone app, and the collection and assay of the kratom products used by participants during EMA. Here, we describe these methods, which can be used to investigate myriad drugs or supplements. Recruiting, screening, and data collection occurred between July 20, 2022 and October 18, 2022. During this time, we demonstrated that these methods, while challenging from a logistical and staffing standpoint, are feasible and can produce high-quality data. The study achieved high rates of enrollment, compliance, and completion. Substances that are emerging or novel, but still largely legal, can be productively studied via nationwide EMA combined with assays of shipped product samples from participants. We discuss challenges and lessons learned so other investigators can adapt these methods. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Identifiants
pubmed: 37213182
pii: 2023-73759-001
doi: 10.1037/pha0000656
pmc: PMC10663387
mid: NIHMS1913069
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDA NIH HHS
ID : K99 DA055571
Pays : United States
Références
Behav Res Ther. 2022 May;152:104071
pubmed: 35390535
Drug Alcohol Depend. 2020 Mar 1;208:107849
pubmed: 32029298
Drug Alcohol Depend. 2017 Nov 1;180:340-348
pubmed: 28950240
Am J Drug Alcohol Abuse. 2022 Jul 4;48(4):433-444
pubmed: 35389321
Clin Toxicol (Phila). 2008 Feb;46(2):146-52
pubmed: 18259963
Front Pharmacol. 2022 Mar 01;13:765917
pubmed: 35300296
JAMA. 2017 Nov 7;318(17):1708-1709
pubmed: 29114823
J Forensic Sci. 2019 Nov;64(6):1943-1949
pubmed: 31305953
Drug Alcohol Depend. 2019 Sep 1;202:200-208
pubmed: 31357121
Drug Alcohol Depend. 2012 Jan 1;120(1-3):238-41
pubmed: 21835562
Psychopharmacology (Berl). 2017 Sep;234(17):2631-2642
pubmed: 28593441
Am J Drug Alcohol Abuse. 2023 Jan 2;49(1):85-96
pubmed: 36410029
Exp Clin Psychopharmacol. 2023 Apr;31(2):312-317
pubmed: 35467921
J Psychoactive Drugs. 2015 Nov-Dec;47(5):360-7
pubmed: 26595229
Psychopharmacology (Berl). 2018 Sep;235(9):2713-2723
pubmed: 29980821
J Stud Alcohol Drugs. 2020 Mar;81(2):212-219
pubmed: 32359051
J Affect Disord. 2023 Feb 1;322:125-131
pubmed: 36372127
J Addict Med. 2022 Nov-Dec 01;16(6):666-670
pubmed: 35220331
Drug Alcohol Depend. 2017 Jul 1;176:63-70
pubmed: 28521200
Clin Toxicol (Phila). 2021 Feb;59(2):152-157
pubmed: 32552075
J Psychoactive Drugs. 2017 Nov-Dec;49(5):413-419
pubmed: 28699844
Addiction. 2008 Jun;103(6):1048-50
pubmed: 18482427
Subst Abus. 2014;35(2):184-9
pubmed: 24821356
Assessment. 2023 Apr;30(3):825-846
pubmed: 35016567
ACS Omega. 2022 Dec 21;8(1):761-770
pubmed: 36643502
Am J Drug Alcohol Abuse. 2021 Jul 4;47(4):455-466
pubmed: 33909525
JAMA. 2022 Nov 22;328(20):2007-2008
pubmed: 36331491
Drug Alcohol Depend. 2021 Sep 1;226:108879
pubmed: 34216869
Behav Pharmacol. 2012 Oct;23(7):710-5
pubmed: 22926298
Psychol Assess. 2020 Aug;32(8):768-779
pubmed: 32437190
JAMA Netw Open. 2022 Jul 1;5(7):e2223019
pubmed: 35857320
Addiction. 2022 Aug;117(8):2351-2358
pubmed: 35293047
Behav Ther. 2022 Sep;53(5):1024-1036
pubmed: 35987533
Exp Clin Psychopharmacol. 2022 Dec;30(6):983-996
pubmed: 34735202
Epilepsy Behav Case Rep. 2018 Apr 17;10:18-20
pubmed: 30062086
Am J Drug Alcohol Abuse. 2022 Nov 2;48(6):684-694
pubmed: 35767669